Breast Cancer

Latest News

Pink ribbon for breast cancer | Image Credit: © Andrey Popov - stock.adobe.com
Remote Weight Loss Intervention Reduces Body Weight in Women With Breast Cancer

August 25th 2025

A clinical trial assessing a remote weight loss intervention in women with breast cancer saw a reduction in body weight.

Innovation vs Affordability: Cancer Care’s Cost Crisis and Access Gap
Innovation vs Affordability: Cancer Care’s Cost Crisis and Access Gap

August 21st 2025

Triple-negative breast cancer growth linked to increased adipose tissue and elevated BMI in premenopausal women. | Image Credit: @Chinnapong - stock.adobe.com.jpeg
Triple-Negative Breast Cancers Exploit Fat Cells to Fuel Tumor Growth

August 20th 2025

AI-assisted breast cancer screenings aid in reducing radiologists' workload when certain of it's analysis. | Image Credit: okrasiuk - stock.adobe.com.
AI-Assisted Mammogram Readings Reduce Radiologist Workload, Maintain Performance

August 20th 2025

AI-enhanced mammograms can potentially improve early detection. | Image Credit: Gorodenkoff - stock.adobe.com .jpeg
AI-Enhanced Mammograms Reduce False Negative Breast Cancer Screening Results

August 19th 2025

Advances in CDK4/6 Inhibitor Use in High-Risk Early Breast Cancer: 2024 Updates

Experts discuss the impact of CDK4/G inhibitor use, including medication cost, total care costs, toxicity profiles, and strategies to manage and optimize patient outcomes in high-risk early breast cancer.

Watch the latest AJMC Peer Exchange on Advances in CDK4/6 Inhibitor Use in High-Risk Early Breast Cancer: 2024 Updates

More News

Email being sent
March 17th 2021

What We’re Reading: COVID-19 Screening Guidance; Eli Lilly Verzenio Results; Long-Haul Symptom Improvement

AJMC Staff
The FDA issues updated guidance on the emergency use authorization (EUA) process for COVID-19 screening tools; Eli Lilly releases patient-reported outcome results for Verzenio (abemaciclib) in breast cancer; COVID-19 vaccines possibly improve long-haul symptoms among patients.
Woman having a mammogram
February 15th 2021

As Mammography Screenings Drop, Advanced Breast Cancer Cases Increase in First Months of COVID-19

Jaime Rosenberg
The study, presented at the 2020 San Antonio Breast Cancer Symposium, also found that time to first treatment dropped during this period of the coronavirus disease 2019 (COVID-19) pandemic.
Site Logo
February 8th 2021

A Cue-to-Action Pilot Project to Increase Screening Mammography

John R. Litaker, PhD, MSc, MMedSc Naomi Tamez, BS Wesley Durkalski, MBA Richard Taylor, PhD, MPH
A targeted cue-to-action campaign of outreach, education, and incentive can improve uptake of screening mammography.
Head with missing pieces
January 19th 2021

Mental Illness May Predispose Women With Breast Cancer to Higher Mortality

Maggie L. Shaw
Severe mental illnesses that precede a breast cancer diagnosis may increase the risk of both all-cause and cancer-specific mortality among women with Medicaid coverage.
Alexey Aleshin, MD, Natera
January 13th 2021

Dr Alexey Aleshin Discusses Lingering Struggles in Pinpointing Biomarkers for Breast Cancer Reoccurrence

Alexey Aleshin, MD, senior medical director of Oncology at biotech giant Natera, said that attention on finding biomarkers for metastatic reoccurrence needs to be directed at women with a high risk of this happening.
Multiracial graphic
January 11th 2021

Researchers Identify Possible Source of Inflammatory Response Disparity in Black, White Women With Breast Cancer

Maggie L. Shaw
A more aggressive tumor microenvironment may be to blame for the exaggerated inflammatory response more often seen in Black women with breast cancer compared with White women.
Alexey Aleshin, MD, Natera
January 9th 2021

Dr Alexey Aleshin: Persistent ctDNA Is Highly Predictive of Disease Outcome

Changes in circulating tumor DNA (ctDNA) are indicative of treatment response in early-stage breast cancer, pointed out Alexey Aleshin, MD, senior medical director of Oncology at biotech giant Natera.
Knocked-over pill bottle
January 4th 2021

Risk Factors Identified for Chronic Opioid, Benzodiazepine Use After Mastectomy and Breast Reconstruction

Maggie L. Shaw
An abstract from last month’s San Antonio Breast Cancer Symposium identifies factors linked with longer-term controlled substance use after treatment of breast cancer with mastectomy plus breast reconstruction in women receiving opioids, benzodiazepines, and other sedative/hypnotics.
Alexey Aleshin, MD, Natera
January 1st 2021

Dr Alexey Aleshin: Chemotherapy Is Meant to Eliminate, Reduce Disease Burden

Through neoadjuvant chemotherapy we can downstage tumors, assess drug efficacy, and better segregate women by prognosis status for adjuvant treatment, explained Alexey Aleshin, MD, senior medical director of Oncology at biotech giant Natera.
Chemotherapy-Induced Peripheral Neuropathy in Metastatic Breast Cancer Patients Initiating Intravenous Paclitaxel/nab-Paclitaxel
December 23rd 2020

Chemotherapy-Induced Peripheral Neuropathy in Metastatic Breast Cancer Patients Initiating Intravenous Paclitaxel/nab-Paclitaxel

Brenna L. Brady, PhD Matthew Lucci, MPH Kathleen Wilson, MPH Kathleen M. Fox, PhD Jeffrey Wojtynek, PharmD Chelsea Cooper, PharmD Helen Varker, BS Christina Larson Chebili, MA Igoni Dokubo, MD
We examine the incidence and impact of chemotherapy induced peripheral neuropathy on clinical and economic outcomes in women with metastatic breast cancer initiating intravenous paclitaxel/nab-paclitaxel.
evidence-based oncology
December 23rd 2020

Supplemental Material: Chemotherapy-Induced Peripheral Neuropathy in Metastatic Breast Cancer Patients Initiating Intravenous Paclitaxel/nab-Paclitaxel

Brenna L. Brady, PhD Matthew Lucci, MPH Kathleen Wilson, MPH Kathleen M. Fox, PhD Jeffrey Wojtynek, PharmD Chelsea Cooper, PharmD Helen Varker, BS Christina Larson Chebili, MA Igoni Dokubo, MD
Supplemental materials for article examining the incidence and impact of chemotherapy induced peripheral neuropathy on clinical and economic outcomes in women with metastatic breast cancer initiating intravenous paclitaxel/nab-paclitaxel.
Evidence-Based Oncology
December 23rd 2020

Clinical and Economic Burden of Intravenous Paclitaxel or nab-Paclitaxel for Metastatic Breast Cancer

Brenna L. Brady, PhD Matthew Lucci, MPH Kathleen Wilson, MPH Kathleen M. Fox, PhD Jeffrey Wojtynek, PharmD Chelsea Cooper, PharmD Helen Varker, BS Christina Larson Chebili, MA Igoni Dokubo, MD
This article describes treatment patterns, toxicities, and health care service utilization and costs of women with metastatic breast cancer (mBC) initiating treatment with intravenous (IV) paclitaxel or IV nab-paclitaxel.
Evidence-Based Oncology
December 23rd 2020

Supplemental Material: Clinical and Economic Burden of Intravenous Paclitaxel or nab-Paclitaxel for Metastatic Breast Cancer

Brenna L. Brady, PhD Matthew Lucci, MPH Kathleen Wilson, MPH Kathleen M. Fox, PhD Jeffrey Wojtynek, PharmD Chelsea Cooper, PharmD Helen Varker, BS Christina Larson Chebili, MA Igoni Dokubo, MD
Supplemental materials for the article describing treatment patterns, toxicities, and health care service utilization and costs of women with metastatic breast cancer (mBC) initiating treatment with intravenous (IV) paclitaxel or IV nab-paclitaxel.
FDA
December 23rd 2020

MacroGenics’ Margenza Approved for Metastatic Breast Cancer

Maggie L. Shaw
The FDA has approved Margenza (margetuximab-cmkb) plus chemotherapy as a treatment option for adults with HER2-postive advanced breast cancer.
Top 5 breast cancer articles
December 21st 2020

Top 5 Most-Read Breast Cancer Articles of 2020

Maggie L. Shaw
These top 5 posts from our breast cancer compendium in 2020 show that while much is known about breast cancer, much remains that can help to broaden the knowledge armamentarium.
Alexey Aleshin, MD, Natera
December 18th 2020

Dr Alexey Aleshin: I-SPY 2 Findings Show How We Can Dynamically Monitor ctDNA

Patient plasma samples from this study show residual circulating tumor DNA (ctDNA) correlates with a poor prognosis in women with early-stage breast cancer, explained Alexey Aleshin, MD, senior medical director of Oncology at biotech giant Natera.
Pink breast cancer ribbon with figures
December 14th 2020

Uptick in Early-Stage Breast Cancer Diagnoses Seen Among Minority Women Following ACA Implementation

Maggie L. Shaw
Compared with before the Affordable Care Act (ACA), study results show there was an increase in diagnoses of early-stage breast cancer among younger vs older minority women after the act.
Alexey Aleshin, MD, Natera
December 12th 2020

Dr Alexey Aleshin Highlights the Diagnostic Benefits of ctDNA in Early-Stage Breast Cancer

Circulating tumor DNA (ctDNA) has a host of benefits in treating and managing patients with early-stage disease, noted Alexey Aleshin, MD, senior medical director of Oncology at biotech giant Natera.
Obesity May Fuel 40% Gap in Black, White Breast Cancer Mortality
December 7th 2020

Obesity May Fuel 40% Gap in Black, White Breast Cancer Mortality

Maggie L. Shaw
Overall survival from early breast cancer has steadily been increasing; however, simultaneous increases in obesity and obesity-related comorbidities may have contributed to the survival disparity seen between these patient groups.
Doctor evaluating mammography.
December 5th 2020

Social Determinants of Health May Influence Undiagnosed Breast Cancer Risk

Maggie L. Shaw
Research presented at this year’s annual meeting of the Radiological Society of North America shows the possible impact of food or housing insecurity on follow-up appointments for breast cancer.
Silhouette of pregnant woman
December 1st 2020

Fertility Preservation Linked to Uptick in Live Births Following Breast Cancer

Maggie L. Shaw
Survival after breast cancer is on the rise, thereby emphasizing the importance of discussions that focus on fertility and reproduction among younger survivors.
Puzzle-piece graphic for breast cancer gene
November 27th 2020

10-Year BRCA Testing Decreases, Study Shows

Maggie L. Shaw
Among older women with and without breast and ovarian cancers, testing for the BRCA gene dropped precipitously between 2008 and 2018.
Aditya Bardia, MBBS, MPH, Massachusetts General Hospital
November 25th 2020

Dr Aditya Bardia Highlights Immuno-Oncology Developments for Patients With TNBC

Tecentriq (atezolizumab) was approved in 2019 for PD-L1–positive triple-negative breast cancer (TNBC), said Aditya Bardia, MBBS, MPH, breast medical oncologist, Massachusetts General Hospital, Harvard Medical School.
Group of women
November 19th 2020

Younger, Minority Women With Metastatic Breast Cancer Using More EOL Care

Maggie L. Shaw
Patients younger than 65 years represent close to 40% of deaths from metastatic breast cancer, yet their use of end-of-life (EOL) care has not been thoroughly investigated until now.
Mammography image
November 17th 2020

Women With Dense Breast Tissue May Benefit From Abbreviated Breast MRI

Maggie L. Shaw
Supplemental screening for breast cancer, beyond the standard-of-care mammography, may benefit some women who have dense breast tissue.
HRT Associated With Higher Breast Cancer Risk
November 13th 2020

HRT Associated With Higher Breast Cancer Risk, Study Finds

Rose McNulty
A recent study published in The BMJ suggests that the increased breast cancer risk varies by hormone replacement therapy (HRT) type, but that combined treatments and longer duration might lead to the highest risk.
Bilateral Mastectomy Possibly Linked to Poor Self-Image Among Young Breast Cancer Survivors
November 10th 2020

Bilateral Mastectomy Possibly Linked to Poor Self-Image Among Young Breast Cancer Survivors

Maggie L. Shaw
A recent study of female breast cancer survivors shows that feelings toward body image were consistently worse among those who had a bilateral mastectomy vs breast-conserving surgery.
Elderly woman alone
November 7th 2020

Study Results Point to Possible Survival Link Between Elderly Age, Chemotherapy

Maggie L. Shaw
Having node-positive, estrogen receptor–positive breast cancer indicated a greater likelihood of overall survival following chemotherapy, despite having several comorbidities, after adjustment for confounders.
Breast Cancer Survivor
November 2nd 2020

Black Patients With Breast Cancer May Face Longer Waits, Treatment Duration

Rose McNulty
A recent analysis identified disparities in the start of breast cancer treatment and the duration of treatment in Black women compared with White women.
Aditya Bardia, MBBS, MPH, Massachusetts General Hospital
November 1st 2020

Dr Aditya Bardia: Further Research Is Needed to Understand Resistance to Sacituzumab Govitecan

Despite FDA accelerated approval in April, we still need to learn more about resistance to this antibody drug conjugate, said Aditya Bardia, MBBS, MPH, breast medical oncologist, Massachusetts General Hospital, Harvard Medical School.
<1
...
456789101112
...
14>

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo